Construction of individualized medication model of voriconazole for patients with invasive fungal infection based on sparse plasma concentration

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063992

Enrollment

Unknown

Registered

2022-09-22

Start date

2022-09-23

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematologic malignancy

Interventions

Intervention Group:Voriconazole

Eligibility

Sex/Gender

All

Age

15 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=15 years; 2. Voriconazole is used to treat or prevent invasive fungal infections; 3. The patient should provide at least one blood sample.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients; 2. Use of potent CYP450 inducers or inhibitors such as rifampicin isoniazid, phenytoin, carbamazepine, but not proton pump inhibitors (PPI) during Voriconazole therapy; 3. Patients who lack CYP2C19 genotype, liver and kidney function indexes and other necessary data.

Design outcomes

Primary

Measure	Time frame
plasma;	—

Countries

China

Contacts

Public ContactYang Guoping

ygp9880@163.com+86 13974817168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026